Vivani Reports $15.5 Million in Cash as It Eyes New Funding and a 2027 Drug Trial
Key Facts
Vivani Medical said cash, cash equivalents and restricted cash totaled $15.5 million on September 30, 2026, compared with $20.8 million on June 30, and estimated that its existing liquidity would fund planned operations through the first quarter of 2027. Its filing cited substantial doubt about its ability to continue as a going concern. On November 13, the company's shares, VANI, closed at $1.01. Details of the private placement reported in circulated news, including the number of shares, their price, the buyers and the use of proceeds, could not be verified. Therefore, the financing amount and terms, or any link to the share's closing price, cannot be confirmed.
In drug development, the company announced preliminary results on November 12 from the Phase 1 SLIM-1 trial of its NPM-139 implant, which contains semaglutide. The trial included 10 participants who received the implant and 10 in a comparison group who received the 0.25 mg weekly starting dose of Wegovy. The study lasted four weeks, with the NPM-139 group recording weight loss of 0.79%, compared with 0.82% for the Wegovy group. Vivani said these results were achieved during the short study period, with the implant used in one group and weekly injections in the other. These figures compare the two groups' results in the same limited trial.
On safety, the company said none of the 10 participants who received NPM-139 recorded treatment-related adverse events. In the Wegovy group, five of 10 participants recorded such events, which were gastrointestinal only, according to the company. No serious adverse events were reported in the study. Vivani said the implants were inserted and removed without complications. SLIM-1 was conducted at a single study center in Australia, defining the scope of the clinical data announced by the company.
Pharmacokinetic measurements showed NPM-139 levels peaking about 16 days after the implant was administered, compared with about 2.4 days after the first weekly Wegovy injection. These figures describe the timing of peak drug levels in the two study groups. Chief Executive Adam Mendelsohn said, "More than 50% of GLP-1 therapy users, according to some estimates, discontinue treatment within one year, and gastrointestinal side effects drive a large part of that discontinuation." Mendelsohn linked this estimate to interest in treatment tolerability, while SLIM-1 results showed adverse event rates recorded over four weeks. The reported figures remain the outcome of a short Phase 1 trial.
Vivani plans to advance NPM-139 to a Phase 2 trial to determine the dose and study weight maintenance, and said it expects the trial to begin in 2027. It also plans to explore clinical development in people who have not previously used GLP-1 therapies. In its third-quarter filing, the company said cash, cash equivalents and restricted cash totaled $15.5 million at the end of September, after $20.8 million at the end of June. It estimated that its existing cash resources would fund planned operations only through the first quarter of 2027. This estimate places the next trial plan within a funding horizon set by the company itself.
The company previously completed a private placement in January 2026 involving 1,351,351 common shares at $1.48 per share, according to its filing with the U.S. Securities and Exchange Commission. Net proceeds from that placement were about $2 million. At the time, the company entered into a stock purchase agreement with an entity related to one of its independent directors. The filing provides a financing precedent for the company during the year, but does not establish the details of the placement currently reported in the news. The Phase 2 plan and its expected 2027 start remain upcoming developments announced by Vivani.